Real-World Efficacy and Safety of Four PD-1 Inhibitors in Advanced NSCLC, 2019-2023

A retrospective study of 409 patients with stage IIIB-IV non-small cell lung cancer treated with pembrolizumab, sintilimab, tislelizumab, or camrelizumab between February 2019 and December 2022. The research compares progression-free survival, overall survival, and immune-related adverse events across the four treatments. The dataset was authored by Hanqi Wang and shared under a CC-BY-4.0 license on figshare in April 2026.

Use Cases

• Compare real-world progression-free survival (PFS) and overall survival (OS) for four PD-1 inhibitors in advanced NSCLC.
• Analyze differences in immune-related adverse event (irAE) incidence rates among pembrolizumab, sintilimab, tislelizumab, and camrelizumab.
• Investigate treatment efficacy differences between squamous and nonsquamous NSCLC subtypes in a real-world setting.
• Supplement randomized clinical trial data with observational evidence on immunotherapy safety and effectiveness.

Strengths

• Includes data from 409 eligible patients across four specific PD-1 inhibitors.
• Covers a defined time period from February 2019 to September 2023 with a clear follow-up cutoff.
• Provides specific hazard ratios and p-values for efficacy and safety comparisons mentioned in the description.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The description notes findings are hypothesis-generating due to small subgroup sizes and potential residual confounding.

Provenance

Source

Single-center retrospective study, author Hanqi Wang.

Collection Method

Retrospective screening of patient records.

Time Range

Patient treatment from February 1, 2019, to December 31,我们发现 2022; follow-up until September 15, 2023.

Freshness

Last updated 2026-04-28 04:29:08; freshness should be verified.

Geography

Geography is not specified in the input.